-
KALA BIO | Stock Price Up Today 43%+, Get Ready For A Move
NASDAQ: KALA Introduction to KALA BIO and its recent stock performance Investors and traders have been closely monitoring the recent surge in KALA BIO’s stock price, which has seen a remarkable 43% increase. KALA BIO, a pharmaceutical company focused on developing innovative therapies, has captured the attention of the market with its promising advancements. In…
-
Vanda Pharmaceuticals | Announces U.S. FDA Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis
NASDAQ: VNDA 1. Introduction to Vanda Pharmaceuticals’ new drug application for Tradipitant Vanda Pharmaceuticals, a leading biopharmaceutical company, has recently announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for Tradipitant, a potential breakthrough treatment for gastroparesis. This acceptance marks a significant milestone in Vanda Pharmaceuticals’ efforts…
-
NeuroSense | Reporting Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
NASDAQ: NRSN Introduction NeuroSense, a groundbreaking biopharmaceutical company, is set to release the highly anticipated topline results of its Phase 2b clinical trial for ALS (Amyotrophic Lateral Sclerosis) on December 5, 2023. This milestone event marks a significant step forward in the search for new treatment options for this devastating disease. In this article, we…
-
RxE2 | Revolutionizes Clinical Trials with Groundbreaking AI-led Technology Platform and Marketplace
Introduction In the world of medical advancements, clinical trials play a crucial role in testing new drugs, treatments, and procedures to ensure their safety and efficacy. However, the traditional approach to conducting clinical trials is often time-consuming, costly, and resource-intensive. Enter RxE2, an innovative technology platform and marketplace that is revolutionizing the way clinical trials…
-
IDEAYA | Announces Agenda for Investor R&D Day Webcast on December 4, 2023
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company dedicated to the discovery and development of targeted therapeutics, is pleased to announce the agenda topics for its upcoming Investor R&D Day. This highly anticipated webcast event, hosted by IDEAYA, will take place on Monday, December 4, 2023, from 8:00 am to 9:30 am…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF DECEMBER 3-9, 2023
December 2, 2023 EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE Conference 12/05/2023 JAGX 27.4 9,151 $0.36 Conference 12/07/2023 BMEA 43.2 25,780 $16.68 FDA Event 12/08/2023 BCLI 52.0 5,135 $0.26 Conference 12/09/2023 APTO 32.4 76 $2.66 Conference 12/09/2023 INCY 27.1 38,201 $54.02 WEEK: 12/03/2023 – 12/09/2023
-
Neurocrine Biosciences | Hosting Analyst Day on December 5, 2023
NASDAQ: $NBIX Neurocrine Biosciences to Host Analyst Day on December 5, 2023 Have you heard the news? Neurocrine Biosciences, a leading biopharmaceutical company, is set to host an Analyst Day on December 5, 2023. This highly anticipated event will bring together analysts, investors, and industry experts to explore Neurocrine Biosciences’ latest developments and future prospects.…
-
Intensity Therapeutics | Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium
NASDAQ: INTS Intensity Therapeutics, a biotechnology company dedicated to developing innovative cancer therapies, has been selected to present at the prestigious Spotlight Oral Presentations. This recognition highlights the immense potential of the company’s scientific breakthroughs and further establishes its position as a leader in the field of oncology research. The selection also underscores the intelligence…
-
NeuroBo | Participating in Investor Conferences in December
NASDAQ: NRBO NeuroBo, a clinical-stage biotechnology company specializing in treatments for neurodegenerative diseases, has recently announced that it will be attending several investor conferences during the month of December. This move represents an exciting opportunity for the company to showcase its groundbreaking research and attract potential investors. With a focus on developing novel therapeutics for…
-
Jaguar Health | Presents December 5 at the MedInvest Oncology Investor Conference
Jaguar Health, a leading pharmaceutical company specializing in innovative treatments for various diseases, is set to present at the prestigious MedInvest Oncology Investor Conference on December 5. This highly anticipated event brings together top experts, investors, and industry leaders in the field of oncology. Jaguar Health’s participation at this conference is a testament to their…
-
Soligenix | Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet’s Disease
NASDAQ: SNGX Introduction to Soligenix’s Phase 2 Clinical Trial Soligenix, a biopharmaceutical company focused on developing innovative therapies, has recently received FDA Investigational New Drug (IND) clearance for the Phase 2 clinical trial of Dusquetide in the treatment of aphthous ulcers in Behçets Disease. This clearance marks a significant milestone in the development of potential…
-
Carisma Therapeutics | Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte
NASDAQ: CARM Carisma Therapeutics, a leading biotechnology company committed to developing innovative cancer treatments, recently made a groundbreaking announcement. The company has successfully obtained clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. This is a significant milestone for Carisma Therapeutics, as it paves the way for the…
-
Biomea Fusion | Presenting New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
NASDAQ: BMEA BMF-219 is an investigational novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 2 diabetes STOCK & PRESS RELEASE INFO
-
BrainStorm Cell Therapeutics | Announces FDA Advisory Committee Meeting to Review NurOwn® PDUFA Target Action Date Scheduled for December 8, 2023
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) announced that the US FDA has granted the company a meeting to discuss the regulatory path forward for NurOwn® in ALS. The meeting, scheduled for December 6, 2023, will focus on plans for a Special Protocol Assessment (SPA) for a confirmatory Phase 3 trial in ALS. BrainStorm aims to…
-
Arcutis Biotherapeutics | FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
NASDAQ: ARQT WESTLAKE VILLAGE, Calif., April 18, 2023 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S. Food and Drug Administration (FDA) has accepted for review the company’s new drug application (NDA) for roflumilast foam 0.3% for the treatment of seborrheic…
-
Incyte | Spotlighting More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
Incyte (NASDAQ:INCY) will present more than 40 abstracts at the ASH 2023 conference, featuring data from its hematology and oncology products. The Plenary Scientific Session will showcase the results of the AGAVE-201 trial evaluating axatilimab in patients with chronic GVHD. Incyte will also host an analyst and investor event to discuss the key data presentations…
-
Aptose Biosciences | Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
NASDAQ: APTO Aptose Biosciences Inc. announced that clinical data for tuspetinib has been selected for oral presentation at the 65th American Society of Hematology Annual Meeting. The presentation will include safety and efficacy data from Aptose’s ongoing APTIVATE trial of tuspetinib in relapsed/refractory acute myeloid leukemia patients. The presentation will take place on December 9,…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF OCTOBER 29 – NOVEMBER 4, 2023
October 28, 2023 EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE Conference 11/02/2023 ARDX 22.5 27,193 $3.49 Conference 11/02/2023 ELDN 44.2 278 $1.59 Conference 11/03/2023 ACET 36.3 90 $1.26 Conference 11/03/2023 AUPH 23.5 11,055 $7.19 FDA Event 11/04/2023 CRBP 94.6 6,911 $5.21 WEEK: 10/29/2023 – 11/04/2023
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF OCTOBER 22-28, 2023
October 20, 2023 EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE FDA Event 10/22/2023 REGN 3.0 600 $808.47 Conference 10/22/2023 RVMD 37.7 33,800 $27.97 Conference 10/23/2023 HARP 52.4 307 $6.88 FDA Event 10/26/2023 CPRX 13.9 2,074 $12.80 WEEK: 10/22/2023 – 10/28/2023
-
Rocket Pharmaceuticals | Unlocking the Potential: RP-L201 and its FDA Designations – A Breakthrough in Pediatric Medicine
NASDAQ: RCKT Rocket Pharmaceuticals has achieved significant milestones with their groundbreaking therapy, RP-L201. The FDA has granted several prestigious designations to RP-L201, including Regenerative Medicine Advanced Therapy (RMAT), Rare Pediatric, Fast Track, and Orphan Drug designations. These designations highlight the immense potential of RP-L201 in treating pediatric patients and emphasize the urgent need for innovative…
-
Aquestive Therapeutics | FDA Acceptance of Libervant™ for Treatment of Seizure Clusters in Young Patients
NASDAQ: AQST The FDA has recently accepted the New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film, aiming to tackle the treatment of seizure clusters in children between the ages of two and five. This development provides hope for young patients and their families who have pbeen struggling with the challenges of managing seizure clusters.…